The journalist who wrote this (bemoaning the fact that we don't use rapid tests in Australia and, in any case, should we?) is obviously completely unaware of Anteo. Completely. Unaware.
I believe the company could have been a bit more proactive to "get the message out" about progress to date. I know the recent good results were picked up by a couple of biotech news sites but, apart from that, crickets really. Hence articles like this.
ADO Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
